Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Astrazeneca Ord Shs AZNCF

AstraZeneca PLC is a science-led biopharmaceutical company. It discovers, develops, and commercializes prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, respiratory and immunology and vaccines and immune therapies. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its biopharmaceuticals products include Farxiga, Crestor, Breztri and others. Its investigational vaccine candidate IVX-A12, which targets both respiratory syncytial virus and human metapneumovirus. Its oncology candidate includes FPI-2265 targeting prostate specific membrane antigen for metastatic castration resistant prostate cancer, which is in a Phase II trial. It also discovers, develops, and manufactures T-cell receptor therapies. Its Eneboparatide is an investigational therapeutic peptide.


OTCPK:AZNCF - Post by User

Bullboard Posts
Post by GermanInvestorson Sep 22, 2011 2:23am
1936 Views
Post# 19070105

15 High Yield Large Caps With Best Margin

15 High Yield Large Caps With Best MarginHigh Yield Large Capitalized Stocks With Best Operating Margin by Dividend Yield - Stock, Capital, Investment. Here is a current sheet of large capitalized stocks (market capitalization of more than USD 10 billion) with a dividend yield of more than 5 percent and high margins. The operating margin of the observed companies is at least 25 percent. 15 stocks fulfilled these criteria of which 7 have a dividend yield of more than 7 percent.

Here is the table with some fundamentals:
15 High Yield Large Caps With Best Margin....

Take a closer look at the full table of 15 high yield large caps with best margin. The average price to earnings ratio (P/E ratio) amounts to 12.4 while the average forward P/E ratio is 9.6. The dividend yield has an average value of 7.5 percent. Price to book ratio is 3.7 and price to sales ratio 3.1. The operating margin amounts to 34.1 percent.


Related stock ticker symbols:
NLY, STD, TEF, WBK, SCCO, BBVA, SID, MO, AZN, NGG, CHT, RAI, HCP, STO, CM


Selected Articles:
· Best European Dividend Stocks With Margins Over 25 Percent
· 8 Cheap Growth Stocks With High Margins And Dividend Yields
· High Yield Large Caps With Biggest ROE
· 17 Large Cap High Yields Close To 52-Week High
· 14 Big Stocks With High Margins And Dividend Yields

Bullboard Posts